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Malaria generally occurs in tropical and 
subtropical areas, it is commonly associated 
with poverty and represents a major burden to 
economic and social development.[1] The 
World Health Organization (WHO) estimates 
that there are over 200 million cases of malaria 
each year with 80% of cases and 90% of 
deaths estimated to occur in the African 
region.[1]  
 
Effective malaria control is hampered by 
increasing resistance of malaria to the 
available drugs.[2] However, resistance to 
currently available anti- malarial drugs has 
seriously reduced the effectiveness of the 
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Background: The emergence and spread of drug-resistant Plasmodium falciparum is 
a major problem of public health concern. Due to the high incidence of parasite 
resistance to antimalarial drugs, artemisinin-based combination therapies (ACTs) have 
now replaced those failing drugs in order to combat the growing drug resistance. Aim: 
This study is undertaken to detect resistant strains of P. falciparum to artemisinin in 
infected human blood in Owo. Methods: A total of 1000 participants took part in the 
study. Falciparum malaria was confirmed by microscopic examination of Giemsa-
stained blood samples from patients who presented with fever at Federal Medical 
Centre, Owo, Ondo state, Nigeria. Molecular methods were employed to detect a 
marker of resistance of P. falciparum to artemisinins: Parasite DNA was extracted from 
patient blood using Tris-EDTA buffer-based extraction method. Amplification was 
carried out by Nested Polymerase Chain Reaction followed by Restriction Fragment 
Length Polymorphisms (PCR/RFLP) for the detection of falciparum sarco/endoplasmic 
reticulum calcium-dependent ATPase (SERCA) PfATPase6 gene mutation. Results: 
The result showed that resistant PfATPase6 gene which codes for artemisinin 
resistance was not present in the population studied. Conclusion: Since there was no 
resistant gene detected in the population studied, it could be said that artemisinin 
resistance has not yet developed in this area and subsequent monitoring of resistance 
pattern to artemisinin based therapy is advised in order to detect and prevent its 
spread. 
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drugs.[3] In 2006, the World Health 
Organization officially recommended that 
Artemisinin (ART)-based combination 
therapies (ACTs) be adopted as first-line 
treatment of uncomplicated malaria caused by 
Plasmodium falciparum.[4] This 
recommendation came in response to the 
global spread of resistance to the former first-
line anti-malarial Chloroquine (CQ) and 
Sulfadoxine–Pyrimethamine (SP).[5] Following 
increased CQ and SP resistance, artemisinin 
and its derivatives gradually became the 
mainstay of falciparum malaria therapy.[5] 
Besides, previous experiences with other anti-
malarial drugs showed that resistance appears 
after long-term use.[5] 
 
Reports of the reduced Artemisinin sensitivity 
of P. falciparum parasites in known foci in 
Cambodia and Thailand and new suspected 
foci in Myanmar and Vietnam may suggest a 
decline in ACT efficiency.[6,7] Previous work 
discovered a large region in one of the 
parasite's chromosomes that was linked to 
resistance, by looking for genetic variants in 
the parasite associated with their response to 
artemisinin.[8] Therefore, due to the essential 
role of ACT in malaria control and elimination, 
it is crucial to have a regular surveillance of 
resistance to determine whether resistance to 
artemisinin has developed or not [8].   
 
Since the first disclosure of artemisinin to the 
rest of the world in 1979, several more potent 
derivatives have been synthesized, including 
Arthemether, Artemotil, and Artesunate.[9] 
These artemisinin derivatives possess several 
important pharmacological characteristics, 
including rapid onset of action, short half-life, 
activity against the broadest range of stages in 
the life cycle of the malaria parasite and an 
excellent safety profile.[9] Importantly, 
Artemisinin derivatives can kill gametocytes, 
the sexual stage of parasites, in the human 
circulation system.[10] Artemisinins have been 
widely used in parts of China since their initial 
discovery in the 1970s.[11] In endemic regions 
in Southeast Asia, Artemisinins have been 
deployed in the form of ACTs since the 
1990s.[11] Meanwhile, in many endemic 
regions of Africa, the introduction of ACTs was 
delayed until the mid-2000s due to financial 
challenges, a lack of political will, and logistical 
problems in ACT implementation.[11] Since 
then, ACTs have been widely adopted in most 
endemic regions, along with other control 
measures and the use of ACTs has 
undoubtedly contributed to a substantial 
reduction in malaria burden.[11] 
 
Molecular markers are recommended as the 
earliest technique to detect emerging drug 
resistance, therefore the identification and 
monitoring of genes and mutations, which 
correlate with resistance to artemisinin and its 
derivatives are essential for the evaluation and 
monitoring of ACT.[12]  
 
ACTs have become the standard for treatment 
of malaria in sub-Saharan Africa. All ACTs 
combine a short-acting artemisinin with a long 
acting partner drug, and continued success of 
these regimens depends on activity of both 
component drugs. Prolonged circulation of 
artemisinin partner drugs suggests that 
selection of resistance to these agents may 
occur readily.[13] Thus, the need for regular and 
comprehensive surveillance including 
molecular tests, of resistance is a high 
priority.[13] Only limited information on clinical 
resistance to artemisinin has been reported in 
Nigeria. Therefore, as ACT become widely 
used in sub-Saharan Africa, predicting the 
emergence and spread of resistance is 
necessary for planning malaria control and 
instituting strategies that might delay the 
emergence of resistance.[14] This study is 
undertaken to detect resistant strains of P. 
falciparum to artemisinin in infected human 




Study area  
The study was conducted at Federal Medical 
Centre, Owo. Owo is a town in Ondo state, 
situated at the South-Western Nigeria, latitude 
7.1962o and longitude 5.58681o at an 
elevation/altitude of about 400 meters. It is at 
the southern edge of the Yoruba hills, and at 
the intersection of roads from Akure, Kabba, 
Benin City and Siluko.[15] 
 
Malaria is present throughout the year with a 
marked increase during the raining season 
(that is April to October). Approval for the 
study was obtained from Federal Medical 
Centre, Owo and ethical clearance 
(FMC/OW/380/VOL.XXV/59) was issued by 
the Ethical and Research Committee. 
Suspected malaria carriers attending Federal 
Medical Centre, Owo were screened for P. 
falciparum parasitaemia. The initial screening 
for P. falciparum was conducted using 
microscopic observation of thin and thick 
Giemsa-stained blood films and those who 
tested positive for P. falciparum were recruited 
in the study. Samples were analysed at 
Institute of Advance Medical Research and 
Training, Ibadan.  
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Blood sample collection procedure 
Blood samples were collected from 1000 
malaria individuals who have been treated with 
Artimisinin in the last 48 months at Federal 
Medical Centre, Owo. No age restriction was 
applied. After confirmation of P. falciparum 
infection with different parasite densities, by 
microscopic observation of thin and thick 
Giemsa-stained blood films, 1 ml of venous 
blood was collected into vacutainer tubes 
containing EDTA, a sub-sample of this was 
spotted onto Whatman No 3 filter paper.[16] 
The filters were air dried and packed in sealed 
plastic bags and stored at 4oC until further 
analysis.[16] Patients with severe disease, co 
infection, infection with other malaria species, 
anti malarial-drug use within 48 hours before 
enrollment, or known allergies to ACT were 
excluded. The protocol was reviewed and 
approved by the Ethical and Research 
Committee, Federal Medical Centre, Owo and 
all participants provided informed consent.  
 
Sample size determination 
One hundred thousand samples were studied. 
The sample size was determined using the 
formula N = 4pq/l2; where N= sample size;
 P = 
prevalence from previous study q = 1-p and l = 
permissible error (5% of p) 
 
Extraction of parasite DNA  
Tris-Edta buffer-based extraction 
Tris-EDTA buffer, composed of 10 mM Tris, 
pH 8.0 (Tris-base plus Tris-HCl) and 0.1 
Mm.[17] EDTA in distilled water, was prepared 
and kept at room temperature. Punches of 
same dimension (4 mm in diameter) were 
taken from individual dried blood spots (four 
punches from each spot) using a sterile biopsy 
punch (Kai Industries Co., Ltd., Oyana Seki 
City, Japan).[17] Each filter paper punch was 
placed in an eppendorf (Hamburg, Germany) 
tube, soaked in 65 µL of TE buffer, and 
incubated at 50°C for 15 minutes.[17] The 
punches were than pressed gently at the 
bottom of the tube several times, using a new 
pipette tip for each punch and heated at 97°C 
for 15 minutes to elute the DNA. The DNA 
extract was taken into eppendorf tubes and 
was kept at 4°C for use within a few hours.[7,8] 
 
Polymerase Chain Reaction 
The fragment of PfATPase6 gene was 
amplified by nested PCR with specific 
oligonucleotide primers, followed by two 
separate amplifications. The final 
concentration of the PCR mixture for the nest 
1 or primary amplification was 1× PCR buffer, 
2mM MgCl2, 125 µM dNTP, 25 nM of each 
primer (F/R), and 1X dream Taq green DNA 
polymerase. One microliters of DNA template 
was added to a reaction volume of 19µL.[19] 
The nest 2 or secondary amplifications was 
done  in a 20µL reaction volume containing 1× 
PCR buffer, 1mM MgCl2, 125µM dNTP, 125 
nM of each primer (F/R), and 1X dream Taq 
green DNA polymerase.[26] The product of the 
first amplification was used as the template for 
the second PCR (1µL/reaction). For primary 
amplification, the primers were designed using 
primer 3 plus software and are FW-Ope1 5’-
GGA AGA GGT TAT TAA GAA TGC-3’ and 
RV-Ope2 5’-GCT TCA ACA TTT CCT TCA 
TC-3’. For secondary PCR amplification the 
primers are FW-Ope3 5’-TAT TAG ATA TGA 
AAC ATA AAA ATC-3 and RV-Ope4 5’-GGA 
GTT TTA TTA CCA ACA CTC AAT TCA-3.[19] 
Secondary PCR products were digested at 37 
o C by XbaI restriction enzymes- Thermo 
fisher: as recommended by the 
manufacturer.[8,13] The cycling profile consisted 
of initial denaturation at 98o C for 5 minutes 
followed by 35 cycles at 98o C for 1 second, 
59.6o C for 5 seconds and 72o C for 15 
seconds and a final extension at 72o C for 1 
minute using ABI 9700. The PCR products 
were subjected to electrophoresis on 2% Bio-
Rad gel (Bio-Rad document system, 
Rockland), stained with ethidium bromide, and 
visualized by ultraviolet transillumination. 
Restriction digests were loaded in 15μl 
volumes per lane. Band sizes were measured 




Of the total 1000 participants recruited for the 
study, 64% were female and 36% male (figure 
1). Participants were between 1-75 years 
(table1). Participants were on different 
antimalaria drugs; 40% were on artesunate, 
26% and 9% on coartem and lonart 
respectively. Twenty five percent were 
however treatment naive before sampling 
(figure 2). 
 
Parasites DNA extracted from blood spot on 
FTA CARDS using Tris-EDTA based buffer 
extraction method were amplified with primers 
specific for PfATPase6 gene. The first round of 
amplification resulted produced a 285bp 
amplicon and the secondary amplification 
produced an amplicon of 147bp. All the 1000 
(100%) isolates carried the wild type allele, 
which shows that there are no S769N 
mutations for PfATPase6 gene in this region 
presently.  
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Figure 1: Gender distribution of study participants  
 
 
Table 1: Age distribution of the study participants  
  Age  No (%) 
1 – 15 254 (25.4) 
 16 – 30  233 (23.3) 
 31 – 45  221 (22.1) 
 46 – 60  151 (15.1) 






    
   Figure 2: Category of antimalaria regimen used by study participants 
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Figure 3: DNA bands of falciparum sarco/endoplasmic reticulum calcium-dependent ATPase 







Figure 4: DNA bands of PfATPase6 gene in the secondary amplification 
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Anti-malarial drug resistance is the single most 
important threat to global malaria control. 
Understanding artemisinin molecular basis is 
thus essential for determining treatment 
strategies, mapping the spread of resistance 
and guiding elimination.[20,21] Mutations or 
amplification of genes encoding transporters or 
target enzymes have been identified as 
resistance mechanisms to other anti-malarial 
drugs.[18] It is possible that resistance to 
Artemisinin is unlike these classical 
mechanisms in vitro but instead results from a 
complex series of genetic and epigenetic 
events affecting multiple pathways.[17] 
Plasmodium falciparum, which causes the 
most life-threatening malaria syndromes, has 
developed resistance to almost every class of 
anti-malarial compounds.[1] Strong evidence 
has shown that resistance to artemisinin may 
depend on single nucleotide polymorphisms in 
the drug's putative chemotherapeutic target 
known as SERCA type ATPase protein.[26] It 
has been shown that residues S769N, L263E, 
E431K and A623E are associated with 
resistance to artemisinins. A total of one 
hundred percent samples that were positive for 
P. falciparum by microscopy were subjected to 
PCR genotyping for the PfATPase codon 
S769N mutation. All the 1000 (100%) isolates 
carried the artemisinin sensitive wild type 
allele, S769. This observation is similar to 
those documented in previous studies[23,24] in 
several African countries where artemisinin 
and its derivatives are used as first line of 
treatment of uncomplicated malaria. This study 
is also in accordance with findings from Kefas 
and colleagues who reported no S769N or 
A623E in 1205 subjects studied in Tanzania, 
similarly the findings from a Kenyan study 
conducted by Laura et al. in 2011.[22,25,26] 
Observed drug failure in most previous studies 
could have been due to re-infections and not 




Since there was no artemisinin resistant gene 
detected in this study, it was therefore 
concluded that the drug still remains effective 
antimalaria in this area. As there are no 
confirmed molecular markers of resistance to 
ACTs, continuous analysis of malaria parasites 
resistance to drugs offers the best means of 
tracking emerging resistance to ACTs. 
Educational campaigns should be targeted to 
further create awareness on the severity of the 
infection, to train communities on how to 
prevent malaria, and to inform on the 
importance of early diagnostic and compliance 
of treatment. Also, further screening of clinical 
samples from endemic areas for other genes 
that could confer resistance to ACTs and 
active surveillance of clinical response to ACT 
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